An observational study in Malignant Melanoma, sponsored by Royal Marsden NHS Foundation Trust. Status unknown at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2009-10-27.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.
Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the largest comprehensive cancer centre in Europe. In addition to an in-house drug development program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In order to investigate the optimal use of novel molecularly targeted agents, access to clinical tumour samples is needed in order to determine which particular cancer type expresses a molecular "signature" that may indicate potential therapeutic utility. Understanding such signatures should accelerate the registration of new drugs for routine cancer therapy; offering the potential of selecting those patients with tumour types most likely to benefit from therapy. Furthermore, new insights into disease biology may be gained.
Main research question/ objective - Are there features of primary melanoma or lymph node metastases that predict subsequent clinical outcome better than existing markers?
3,005 studies on the registry are indexed under Melanoma; 519 are open to participants now.
This study's planned enrollment of 500 is above the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →Royal Marsden NHS Foundation Trust is the lead sponsor of 262 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital
Exclusion Criteria:
Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
Given that the nature of the research is qualitative, there is no primary outcome measure.
This study is status unknown, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust